Revance Therapeutics

Botox and the value of never-ending profits

Abbvie’s bid for Allergan shows that the Botox franchise is impenetrable. The market agrees.

Snippet roundup: Mylan lines up Botox biosimilar but Vernalis sinks

December 06, 2017

Revance data erase frowns for now

November 03, 2017

Upcoming events – Revance’s phase III challenge and round two for Axovant

April 03, 2014

Biotech floats hint at a narrowing gap between perception and reality

April 01, 2014

Biotech’s record-breaking quarter shines spotlight on sustainability

February 10, 2014

IPO boom sees biotechs going where the money is

February 05, 2014

Soon-to-be-publics top VC rounds of 2013 while seed funding shows an uptick

February 04, 2014

Venture investments stabilise in 2013 but the winners increasingly take all

January 03, 2014

Pharma business development news over Christmas

December 05, 2013

Juno’s bumper A round stands out in biggest VC raises of the decade

Load More